...two of the world’s leading experts in Parkinson’s disease and stem cell research...
Scottsdale, Arizona (PRWEB) August 17, 2012
QualityStocks would like to highlight International Stem Cell Corporation (OTCBB: ISCO), focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs).
In the company’s news yesterday,
International Stem Cell Corp. announced that Professor Evan Snyder and Dr. Rosasio Sánchez-Pernaute are now scientific advisors on the company’s Parkinson’s disease program.
Evan Snyder, MD, PhD is a Professor at the Sanford-Burnham Medical Research Institute and director of Sanford-Burnham’s stem cell program and research center. Regarded as one of the pioneers of stem cell research, particularly with regard to regenerative medicine applications, Prof. Snyder is an expert on Parkinson’s disease (PD). In fact, he was one of the first scientists to identify neural stem cells and to document the ability of stem cells to migrate to injured or diseased regions of the brain. Prof. Snyder is a recipient of an Early Translational Award from the California Institute for Regenerative Medicine (CIRM) to research into cell based therapies for PD.
Rosario Sánchez-Pernaute, MD, PhD is an internationally recognized expert on the use of stem cells to treat Parkinson’s disease. While Assistant Professor in Neurology at Harvard Medical School Dr. Sánchez-Pernaute was one of the first scientists to demonstrate the possibility of using parthenogenetic stem cells to treat the causes of PD in a non-human primate model.
“We are extremely fortunate to work with two of the world’s leading experts in Parkinson’s disease and stem cell research,” say Dr. Ruslan Semechkin, Vice President of Research and Development, “Prof. Snyder and Dr. Sánchez-Pernaute will add invaluable expertise to our Parkinson’s disease program and provide input into our first non-human primate pre-clinical study which uses the most reliable and predictive model of Parkinson’s in humans.”
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.